2-aminothiazole has been researched along with Dementias, Transmissible in 5 studies
2-aminothiazole: RN given refers to parent cpd; structure
1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prototypical PrP prion diseases are invariably fatal, and the search for agents to treat them spans more than 30 years, with limited success." | 2.55 | Developing Therapeutics for PrP Prion Diseases. ( Giles, K; Olson, SH; Prusiner, SB, 2017) |
| " Absolute bioavailability ranged from 27-40%." | 1.39 | Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. ( Benet, LZ; Dalvie, DK; Elepano, M; Fife, KL; Freyman, Y; Gallardo-Godoy, A; Gever, JR; Giles, K; Huang, Y; Jacobson, MP; Li, Z; Prusiner, SB; Rao, S; Renslo, AR; Silber, BM, 2013) |
| "Recently, we described the aminothiazole lead (4-biphenyl-4-ylthiazol-2-yl)-(6-methylpyridin-2-yl)-amine (1), which exhibits many desirable properties, including excellent stability in liver microsomes, oral bioavailability of ∼40 %, and high exposure in the brains of mice." | 1.39 | 2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease. ( Bryant, C; Dolghih, E; Elepano, M; Gallardo-Godoy, A; Gever, JR; Jacobson, MP; Li, Z; Prusiner, SB; Rao, S; Renslo, AR; Silber, BM; Widjaja, K, 2013) |
| "Prion diseases are fatal, untreatable neurodegenerative diseases caused by the accumulation of the misfolded, infectious isoform of the prion protein (PrP), termed PrP(Sc)." | 1.36 | Discovery of 2-aminothiazoles as potent antiprion compounds. ( Ghaemmaghami, S; May, BC; Prusiner, SB; Renslo, AR, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silber, BM | 2 |
| Rao, S | 2 |
| Fife, KL | 1 |
| Gallardo-Godoy, A | 2 |
| Renslo, AR | 4 |
| Dalvie, DK | 1 |
| Giles, K | 2 |
| Freyman, Y | 1 |
| Elepano, M | 2 |
| Gever, JR | 2 |
| Li, Z | 2 |
| Jacobson, MP | 2 |
| Huang, Y | 1 |
| Benet, LZ | 1 |
| Prusiner, SB | 4 |
| Bryant, C | 1 |
| Dolghih, E | 1 |
| Widjaja, K | 1 |
| Ghaemmaghami, S | 2 |
| Russo, M | 1 |
| Olson, SH | 1 |
| May, BC | 1 |
2 reviews available for 2-aminothiazole and Dementias, Transmissible
| Article | Year |
|---|---|
Successes and challenges in phenotype-based lead discovery for prion diseases.
Topics: Animals; Brain; Creutzfeldt-Jakob Syndrome; Disease Models, Animal; Drug Discovery; Drug Evaluation, | 2014 |
Developing Therapeutics for PrP Prion Diseases.
Topics: Animals; Disease Progression; High-Throughput Screening Assays; Humans; Mice; Molecular Targeted The | 2017 |
3 other studies available for 2-aminothiazole and Dementias, Transmissible
| Article | Year |
|---|---|
Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Avail | 2013 |
2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.
Topics: Administration, Oral; Animals; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Humans; M | 2013 |
Discovery of 2-aminothiazoles as potent antiprion compounds.
Topics: Animals; Cell Line, Tumor; Drug Discovery; Enzyme-Linked Immunosorbent Assay; High-Throughput Screen | 2010 |